A similar result was found in bladder cancer where a significant pathologic response to neoadjuvant cisplatin-based chemotherapy was attained in 66% of patients with low/intermediate BRCA1 levels compared with 22% of patients with high BRCA1 levels (P = 0.01) [59]. The gene discussed is BRCA1; the disease is urinary bladder cancer.